AstraZeneca: Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement vs. Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
May 29, 2024
May 29, 2024
WILMINGTON, Delaware, May 29 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
In the overall trial population, survival results numerically favored AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan but did not reach statistical significance
TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population
Results support applications currently . . .
* * *
In the overall trial population, survival results numerically favored AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan but did not reach statistical significance
TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population
Results support applications currently . . .